Scientific Advisory Board

DOUGLAS A. LEVINE, MD

Chair, Scientific Advisory Board & Advisor, Board of Directors

Doug is the Director of Gynecologic Oncology, Head of the Gynecology Research Laboratory and a Professor at NYU Langone Perlmutter Cancer Center. Prior to joining the NYU Langone Medical Center team, Doug was an Associate Attending Surgeon at Memorial Sloan Kettering Cancer Center in New York City. He received his MD from Mount Sinai School of Medicine and completed his residency at Mount Sinai Medical Center and a fellowship at Memorial Sloan Kettering. In addition to his clinical practice, Doug studies cancer prevention, precision medicine, and rare tumors with unmet needs. Doug brings to Tina’s Wish an outstanding level of expertise and leadership in ovarian cancer research and a deep commitment to women’s health. He is one of the Tina's Wish 2017/18 grant recipients.

ROBERT BURGER, MD

Member

Robert Burger is Director of Clinical Research and Fellowship Program in Gynecologic Oncology and Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania. He received his MD from New York University School of Medicine and completed his residency at the Hospital of the University of Pennsylvania and a fellowship at UC, Irvine Medical Center.

JOYCE LIU, MD, MPH

Member

Joyce Liu joined the staff of Dana-Farber and Brigham and Women’s Hospital in 2008, where she is a medical oncologist and clinical investigator in the Gynecologic Oncology Program. She received her MD from Harvard Medical School and completed her residency in Internal Medicine at Brigham and Women’s Hospital, and her fellowship in Hematology Oncology at the Dana-Farber Cancer Institute. Joyce's research focuses on identifying and validating potential therapeutic targets in advanced platinum-resistant ovarian cancer, in an in-vitro setting as well as in a mouse model of ovarian cancer.

Joyce was awarded The Columbia Hospital Research Foundation Annual Award for Research Excellence in Breast, Obstetrical and Gynecologic Disorders. Read more

In the 5th issue of Dana-Farber’s Inside the Institute, Joyce discusses the importance of federal funding after her successful clinical trial, which was funded by the National Cancer Institute, proved that a novel two-drug combination nearly doubled progression-free survival for many women with ovarian cancer. Read Article

#1

deadliest gynecologic
cancer

80%

of women are diagnosed
at an advanced stage

27%

of women have a 5-year
survival rate after an
advanced stage diagnosis